Sleep Medicine · Neurology · Mental Health · June 2026
A comprehensive, medically reviewed reference on Ambien (zolpidem) — covering its pharmacology, FDA-approved indication for insomnia, immediate-release and extended-release formulations, how it compares to other sleep medications, critical safety information, and legal access for patients in the United States and internationally.
| Generic Name | Zolpidem tartrate |
| Brand Names | Ambien (immediate-release) · Ambien CR (extended-release) · Edluar (sublingual) · Zolpimist (oral spray) · Intermezzo (low-dose sublingual) |
| Drug Class | Non-benzodiazepine hypnotic (imidazopyridine) — GABA-A receptor agonist |
| FDA Approval | 1992 (Ambien immediate-release) · 2005 (Ambien CR) |
| DEA Schedule | Schedule IV controlled substance |
| Available Doses | 5 mg · 10 mg (immediate-release) · 6.25 mg · 12.5 mg (extended-release) |
| Standard Adult Dose | 5 mg (women) or 5–10 mg (men), taken immediately before bedtime |
| Extended-Release Dose | 6.25 mg (women) or 6.25–12.5 mg (men), once nightly |
| Onset of Action | 15–30 minutes |
| Duration of Effect | Approximately 6–8 hours — requires a full night's sleep after dosing |
| Half-Life | ~2.5 hours (immediate-release); similar elimination for the extended-release layer |
| Food Interaction | Significant — taking with or after a meal delays onset; should be taken on an empty stomach |
| Alcohol Interaction | Contraindicated — additive CNS depression, impaired judgment, respiratory depression risk |
| Critical Warning | Complex sleep behaviors (sleepwalking, sleep-driving) — FDA boxed warning |
| Generic Available | Yes — widely available in USA since 2007 |
Ambien is the brand name for zolpidem tartrate — a short-acting, non-benzodiazepine sedative-hypnotic approved by the U.S. Food and Drug Administration in 1992 for the short-term treatment of insomnia, specifically difficulty with sleep initiation. It belongs to a chemical class known as imidazopyridines, structurally distinct from benzodiazepines such as diazepam or lorazepam, though it acts on an overlapping receptor system in the brain. Zolpidem is one of the most widely prescribed sleep medications in the United States and is generally reserved for short-term use rather than as a long-term nightly solution.
Ambien is available in an immediate-release tablet, indicated to help patients fall asleep faster, and in an extended-release formulation, Ambien CR, which combines an immediate-release outer layer with a second layer designed to help sustain sleep through the night. Both formulations share the same active ingredient and core safety profile, differing primarily in their release kinetics and their specific indication — sleep onset versus sleep onset and maintenance.
Generic zolpidem entered the U.S. market in 2007, and it is now the standard dispensed form in most pharmacy settings, offered at a fraction of the original branded cost while remaining bioequivalent to Ambien in all pharmacokinetic parameters. Insomnia affects an estimated 30–35% of American adults at some point, with 10–15% experiencing chronic symptoms significant enough to affect daytime functioning. Zolpidem is one of several pharmacological tools available for short-term management of this condition, generally used alongside — not instead of — behavioral sleep interventions.
Zolpidem works by selectively binding to the benzodiazepine site on the GABA-A receptor complex, a subtype known as the alpha-1 subunit, which is heavily represented in brain regions associated with sedation. GABA (gamma-aminobutyric acid) is the primary inhibitory neurotransmitter in the central nervous system; when zolpidem binds to its receptor site, it enhances the inhibitory effect of GABA, increasing chloride ion influx into neurons, hyperpolarizing the cell membrane, and reducing overall neuronal excitability. The net clinical effect is sedation and a reduced latency to sleep onset.
Zolpidem's relative selectivity for the alpha-1 GABA-A subunit — compared to the broader receptor activity of traditional benzodiazepines — is believed to account for its more prominent sedative-hypnotic effect relative to its anxiolytic, muscle-relaxant, and anticonvulsant effects, which are more strongly associated with alpha-2 and alpha-3 subunit activity. This relative selectivity does not eliminate the risk of dependence, tolerance, or withdrawal, but it does distinguish zolpidem's overall pharmacological profile from that of benzodiazepines used primarily for anxiety.
After oral administration on an empty stomach, zolpidem is absorbed rapidly, with peak plasma concentrations reached within 1.5 to 2 hours, and clinical sedative effect often noticeable within 15 to 30 minutes. Its short elimination half-life of approximately 2.5 hours is central to its clinical design — intended to promote sleep onset and then clear from the body before the patient needs to wake, drive, or perform tasks requiring full alertness. Taking zolpidem with or after food significantly delays absorption and reduces peak concentration, which is why it is specifically directed to be taken on an empty stomach.
The original formulation, indicated for difficulty falling asleep. The entire dose is released promptly, producing a rapid onset that is well suited to sleep-initiation insomnia but offers less benefit for patients who fall asleep without difficulty but wake repeatedly during the night.
Ambien CR uses a bilayer tablet: an outer layer that dissolves quickly to promote sleep onset, and an inner layer that releases zolpidem more gradually to help sustain sleep through the night. It is FDA-approved for insomnia characterized by both difficulty falling asleep and difficulty staying asleep, and it must always be swallowed whole — never split, crushed, or chewed — as this disrupts the extended-release mechanism.
Additional zolpidem formulations exist for specific clinical scenarios. Edluar is a sublingual tablet, and Zolpimist is an oral spray — both useful for patients with difficulty swallowing tablets. Intermezzo is a very low-dose sublingual tablet (1.75 mg or 3.5 mg) specifically approved for middle-of-the-night awakening with difficulty returning to sleep, taken only when at least four hours of planned time in bed remain before the patient needs to be awake and alert.
| Feature | Ambien (Zolpidem) | Lunesta (Eszopiclone) | Sonata (Zaleplon) | Trazodone (off-label) |
|---|---|---|---|---|
| Drug Class | Non-benzodiazepine hypnotic | Non-benzodiazepine hypnotic | Non-benzodiazepine hypnotic | Atypical antidepressant |
| DEA Schedule | Schedule IV | Schedule IV | Schedule IV | Not controlled |
| Onset of Action | 15–30 min | 30 min–1 hr | 15–30 min | 30 min–1 hr |
| Half-Life | ~2.5 hours | ~6 hours | ~1 hour | ~7–10 hours |
| Primary Use Pattern | Sleep onset (IR) / onset + maintenance (CR) | Sleep onset and maintenance | Sleep onset only; middle-of-night option | Sleep maintenance (off-label) |
| Next-Day Residual Effect | Low at standard female dose; higher at 10 mg in some patients | Moderate; taste disturbance common | Very low due to short half-life | Can be more pronounced given longer half-life |
| FDA Boxed Warning | Yes — complex sleep behaviors | Yes — complex sleep behaviors | Yes — complex sleep behaviors | No |
| Dependence Potential | Present with nightly long-term use | Present with nightly long-term use | Present with nightly long-term use | Low |
| Generic Available | Yes (since 2007) | Yes (since 2014) | Yes | Yes |
The most clinically relevant differentiators favoring zolpidem are its rapid onset and short half-life, which make it well suited to patients whose primary difficulty is falling asleep rather than staying asleep, and whose schedule allows a full uninterrupted night before needing to be alert. Patients with prominent middle-of-the-night awakenings may be better served by Ambien CR or eszopiclone, while patients seeking a non-scheduled alternative with a gentler dependence profile — often at the cost of a slower onset — may be directed toward trazodone. The choice between agents remains individual and physician-guided, and is frequently revisited over the course of treatment.
Ambien is FDA-approved for the short-term treatment of insomnia in adults, characterized by difficulty with sleep initiation. Ambien CR carries the broader indication of insomnia characterized by difficulty with sleep onset and/or sleep maintenance. Clinical trial data supporting approval demonstrated statistically significant reductions in sleep latency — the time taken to fall asleep — compared to placebo, along with modest improvements in total sleep time and reported sleep quality.
Zolpidem is generally recommended for short-term use, typically a few days to a few weeks, rather than indefinite nightly use. Current clinical guidance emphasizes that pharmacological treatment for insomnia works best as one part of a broader approach that also addresses sleep hygiene, screen exposure before bed, caffeine and alcohol timing, and, where appropriate, cognitive behavioral therapy for insomnia (CBT-I) — which many sleep specialists consider the preferred first-line treatment for chronic insomnia, with medication reserved for short-term or adjunctive use.
Zolpidem is available in 5 mg and 10 mg immediate-release tablets and 6.25 mg and 12.5 mg extended-release tablets. Dosing differs by sex, formulation, age, and hepatic status, reflecting known differences in drug clearance and next-day residual sedation risk observed in post-marketing data.
| Immediate-Release — Women | 5 mg taken once, immediately before bedtime, with at least 7–8 hours remaining for sleep before the patient must be active and alert. Do not exceed 5 mg. |
| Immediate-Release — Men | 5 mg or 10 mg taken once, immediately before bedtime, with at least 7–8 hours remaining before the patient must be active and alert. The lowest effective dose should be used. |
| Extended-Release — Women | 6.25 mg once nightly, swallowed whole. Not to be split, crushed, or chewed. |
| Extended-Release — Men | 6.25 mg or 12.5 mg once nightly, swallowed whole. |
| Elderly Patients (65+) | 5 mg (immediate-release) or 6.25 mg (extended-release) regardless of sex, reflecting increased sensitivity to sedative effects and higher fall risk in this population. |
| Hepatic Impairment | 5 mg (immediate-release) or 6.25 mg (extended-release), with close monitoring. Reduced hepatic clearance prolongs drug exposure and increases next-day sedation risk. |
| Concurrent CNS Depressant Use | Dose reduction and careful monitoring required. Concurrent use with opioids should be avoided where possible; if unavoidable, the lowest effective doses of each medication should be used with close supervision. |
| Middle-of-the-Night Use (Intermezzo only) | 1.75 mg (women) or 3.5 mg (men), only if at least 4 hours of planned time in bed remain before the patient needs to be awake and alert. Not interchangeable with standard Ambien or Ambien CR. |
Regulatory guidance for zolpidem since 2013 has specifically recommended lower starting doses than were originally approved, following data showing that some patients — particularly women, who clear zolpidem more slowly — had next-morning blood levels high enough to impair driving and other activities requiring full alertness. The guiding clinical principle for zolpidem across all formulations is the lowest dose that produces adequate effect, used for the shortest duration necessary, with regular reassessment of ongoing need. Discuss dose, duration, and any signs of reduced effectiveness over time with your prescribing physician.
Ambien should be taken immediately before getting into bed, once the patient is ready to commit to a full night of sleep, and only when at least 7 to 8 hours are available before the next required period of activity, driving, or operating machinery. It should be taken on an empty stomach — taking it with or shortly after a meal delays the onset of action and may reduce its effectiveness for sleep initiation.
Ambien CR tablets must be swallowed whole and never split, crushed, or chewed, as doing so disrupts the extended-release layer responsible for sustaining sleep through the night and can cause an unpredictably rapid release of the full dose. Immediate-release tablets are also swallowed whole with water, though scored formulations may be split only if specifically directed by a prescriber.
Once a dose is taken, the patient should go directly to bed. Attempting to remain awake, work, or engage in activity after taking zolpidem substantially increases the risk of impaired coordination, memory disturbance, and the complex sleep behaviors described in the warnings below. Zolpidem should never be taken unless a full night of sleep is possible — taking it before a short nap, or during travel with an interrupted or short sleep opportunity, is not an approved or recommended use.
Zolpidem's side effect profile reflects its central nervous system depressant mechanism. At standard doses, most adverse effects are related to residual sedation, mild next-day grogginess, and effects on coordination and memory that mirror its intended pharmacological action rather than representing an off-target reaction.
Drowsiness the following day is the most commonly reported effect, occurring more frequently at the 10 mg dose and with extended-release formulations, and is the basis for the lower recommended starting doses in women and elderly patients. Dizziness and mild headache are also frequently reported, typically resolving within the first days of use as the body adjusts to nightly dosing.
Memory impairment, specifically anterograde amnesia for events occurring in the hours after dosing, is a recognized effect of zolpidem and reflects its action on memory-related GABA-A receptor subtypes. This effect is dose-related and is most pronounced if the patient does not go to bed promptly after taking the medication or is awakened during the period of peak drug effect. Diarrhea, nausea, and dry mouth are reported in a modest proportion of patients and are typically mild.
Unpleasant taste and mild lightheadedness on standing may also occur. With extended-release formulations, next-day residual sedation is somewhat more common than with immediate-release tablets, given the additional hours of ongoing drug release, reinforcing the importance of allowing a full 7 to 8 hours before needing to drive or perform tasks requiring full alertness.
The FDA has required a boxed warning — its most serious labeling designation — for zolpidem regarding complex sleep behaviors, including sleepwalking, sleep-driving, preparing and eating food, making phone calls, and engaging in other activities while not fully awake, with no memory of the event afterward. These behaviors have resulted in serious injury and death. They can occur after the first dose or after long-term use, at recommended doses, and the risk is increased with alcohol or other CNS depressants, or if the patient does not go to bed immediately after taking the medication. Any patient who experiences a complex sleep behavior must stop taking zolpidem immediately and contact their physician; the medication should not be restarted without a full clinical reassessment.
Zolpidem can impair driving skills and other activities requiring full alertness the morning after a dose, even in patients who feel fully awake. This risk is highest with the 10 mg immediate-release dose and both extended-release doses, and is elevated in women due to slower drug clearance. Patients should not drive or perform other hazardous tasks until they know how the medication affects them the following morning, and should be especially cautious after any dose increase.
Zolpidem carries a recognized potential for physical and psychological dependence, particularly with nightly use beyond the recommended short-term treatment window, at higher-than-prescribed doses, or in patients with a personal history of substance use disorder. Abrupt discontinuation after regular use can produce withdrawal symptoms, including rebound insomnia, anxiety, tremor, and, in rare cases with prolonged high-dose use, seizures. Discontinuation after extended use should be guided and, where appropriate, gradually tapered by a physician rather than stopped abruptly.
Zolpidem, in combination with other central nervous system depressants — particularly opioids, benzodiazepines, or alcohol — can produce profound sedation, respiratory depression, coma, and death. This combined risk is a leading safety concern in overdose and drug-interaction data for zolpidem and underlies clear labeling recommendations to avoid concurrent use of these substances wherever possible.
Rare reports describe worsening depression, agitation, hallucinations, and, very rarely, suicidal thoughts associated with zolpidem use. Patients with a history of depression or other mental health conditions should be monitored closely, and any new or worsening mood symptoms, unusual thoughts, or behavioral changes during treatment should be reported to a physician promptly.
| Interaction | Mechanism | Clinical Consequence | Management |
|---|---|---|---|
| Alcohol | Additive central nervous system depression | Profound sedation, impaired coordination, respiratory depression, higher risk of complex sleep behaviors | Avoid alcohol entirely on nights zolpidem is taken. |
| Opioids | Additive CNS and respiratory depression | Extreme sedation, respiratory depression, coma, death — carries an FDA warning for the drug class combination | Avoid combination where possible. If necessary, use the lowest effective doses with close medical supervision. |
| Benzodiazepines and other sedatives | Additive GABA-A receptor activity | Compounded sedation, respiratory depression, memory impairment | Avoid concurrent use unless specifically directed and monitored by a physician. |
| Strong CYP3A4 inhibitors | Reduced zolpidem metabolism, elevated plasma levels | Increased sedation and next-day residual effect | Dose reduction may be needed. Includes certain antifungals and protease inhibitors; disclose to prescriber. |
| CYP3A4 inducers | Accelerated zolpidem metabolism | Reduced effectiveness for sleep initiation and maintenance | Rifampicin and similar inducers can reduce zolpidem exposure significantly; alternative treatment may be considered during induction therapy. |
| Antidepressants (SSRIs, SNRIs, particularly sertraline) | Pharmacodynamic and modest pharmacokinetic interaction | Increased zolpidem exposure and additive CNS effects reported with some combinations | Disclose all antidepressant use; dose adjustment may be considered by the prescriber. |
| Antihistamines and other sedating OTC medications | Additive sedative effect | Excessive drowsiness, impaired coordination and memory the following day | Avoid combining with over-the-counter sleep aids, cold and allergy medications containing diphenhydramine, or other sedating agents. |
| Food (meals taken with or after dosing) | Delayed gastric absorption | Delayed onset and reduced peak effect for sleep initiation | Take on an empty stomach, ideally not within several hours of a meal. |
Signs of zolpidem overdose or dangerous combined CNS depression include extreme drowsiness that cannot be roused, slow or shallow breathing, confusion, and loss of coordination. This is a medical emergency, particularly when zolpidem has been combined with alcohol, opioids, or other sedatives. Seek emergency medical care immediately and inform responders of all substances taken, including the timing and dose of zolpidem.
Inability to obtain a full night's sleep: Zolpidem should not be taken unless the patient can devote at least 7 to 8 hours to sleep before needing to be active and alert. Use before shorter sleep opportunities significantly raises the risk of next-day impairment and memory disturbance.
History of complex sleep behaviors: Prior episodes of sleepwalking, sleep-driving, or similar events while taking zolpidem or a related hypnotic represent a contraindication to further use of the same or a similar agent.
Severe hepatic impairment: Zolpidem clearance is reduced, prolonging drug exposure and increasing sedation risk; use requires caution and dose reduction, with severe impairment warranting particular restraint.
Concurrent alcohol or other CNS depressant use: Active use of alcohol, opioids, or other sedating substances on the same night significantly elevates risk and should be avoided.
Severe respiratory impairment: Conditions such as severe sleep apnea or significant respiratory compromise warrant caution given zolpidem's CNS and respiratory depressant potential.
History of substance use disorder: Given zolpidem's dependence potential, patients with a personal history of substance use disorder require careful assessment before initiation and close monitoring during use.
Pregnancy and breastfeeding: Zolpidem crosses the placenta and is present in breast milk; use during pregnancy or breastfeeding should be discussed carefully with a physician, weighing risks and benefits for the specific clinical situation.
Pediatric patients: Not established as safe or effective in patients under 18 years of age.
Known hypersensitivity: Contraindicated in patients with a prior hypersensitivity reaction to zolpidem or any component of the tablet formulation.
Take zolpidem only when a full night of sleep is possible — never before a short nap, a work shift, or travel with an uncertain or interrupted sleep window. Going to bed immediately after dosing meaningfully reduces the risk of memory disturbance and complex sleep behaviors.
Avoid alcohol and other sedating substances on any night zolpidem is taken. This is one of the most consistent risk factors identified in reports of serious adverse events, including complex sleep behaviors and severe CNS depression.
Use the lowest effective dose for the shortest necessary duration. Zolpidem is intended for short-term insomnia management. If sleep difficulty persists beyond a few weeks, or if increasing doses seem necessary to achieve the same effect, this should be discussed with a physician rather than self-adjusted.
Do not stop abruptly after extended regular use. If zolpidem has been taken nightly for an extended period, discontinuation should be guided by a physician, who may recommend a gradual taper to reduce withdrawal risk.
Be alert to signs of next-day impairment, including grogginess, dizziness, or slowed reaction time, particularly after starting treatment, increasing a dose, or switching to an extended-release formulation. Do not drive or operate machinery until you know how the medication affects you the next morning.
Store at room temperature (20–25°C / 68–77°F), away from moisture, heat, and light, and out of reach of children. As a Schedule IV controlled substance, zolpidem should never be shared, and any unused medication should be disposed of through an authorized take-back program rather than kept beyond the course of treatment.
In the United States, Ambien and generic zolpidem are prescription medications classified as Schedule IV controlled substances, available from any licensed pharmacy following a physician consultation. Generic zolpidem, available since 2007, has substantially reduced the cost of treatment while remaining bioequivalent to the branded product. Telehealth consultations for insomnia have expanded significantly, allowing many patients to complete an evaluation, discuss non-pharmacological options alongside medication, and receive a prescription without an in-person clinic visit, though controlled substance prescribing is subject to additional regulatory requirements that vary by state and platform.
For patients whose insomnia is primarily related to difficulty staying asleep rather than falling asleep, discussing the extended-release Ambien CR formulation, or an alternative agent altogether, with a prescriber is worthwhile before committing to long-term use of any single hypnotic.
Internationally, zolpidem is a controlled prescription medication in all major healthcare markets, reflecting both its clinical value and its recognized potential for misuse and dependence. The same standard for legitimate pharmacy sourcing applies universally: a mandatory prescription requirement, a verifiable pharmacy license, transparent pricing, and accountable dispensing records consistent with controlled substance regulations. Sourcing zolpidem, or any controlled sleep medication, from unregulated or unlicensed online sources carries significant risk, including counterfeit or mislabeled products with unpredictable strength and composition.
My Online Med Shop provides genuine, verified Ambien and generic zolpidem sourced exclusively from verified pharmaceutical manufacturers, dispensed strictly against a valid prescription, with secure encrypted checkout, discreet packaging, and 24/7 customer support available for every order.
Zolpidem is typically absorbed rapidly on an empty stomach, with a noticeable sedative effect within 15 to 30 minutes and peak plasma concentration reached within about 1.5 to 2 hours. Because of this rapid onset, it should be taken immediately before getting into bed, not in advance of other activities, and only when a full night of sleep is possible.
Ambien is an immediate-release tablet indicated for difficulty falling asleep, releasing its full dose promptly. Ambien CR is an extended-release bilayer tablet indicated for difficulty falling asleep and staying asleep, with a second layer that releases zolpidem more gradually through the night. Ambien CR must be swallowed whole and never split or crushed, as this disrupts its extended-release mechanism.
Post-marketing data showed that women clear zolpidem from the body more slowly than men on average, resulting in higher next-morning blood levels at equivalent doses and an increased risk of impaired driving and other activities requiring full alertness. In response, regulatory guidance was updated to recommend a lower standard starting dose for women across all zolpidem formulations, a recommendation that remains current.
Zolpidem carries a recognized potential for physical and psychological dependence, which is why it is classified as a Schedule IV controlled substance and is generally recommended for short-term use. Risk increases with nightly use over an extended period, doses higher than prescribed, and in patients with a personal history of substance use disorder. Long-term use should be periodically reassessed with a physician, and discontinuation after extended use should generally be guided rather than abrupt.
Complex sleep behaviors refer to activities performed while not fully awake and with no memory afterward — including sleepwalking, sleep-driving, and preparing or eating food during sleep. The FDA has placed its most serious boxed warning on zolpidem for this risk after cases resulting in serious injury and death. While considered uncommon at recommended doses when the medication is taken correctly, the risk rises with alcohol use, higher doses, and not going to bed immediately after dosing, and any occurrence requires stopping the medication and contacting a physician.
No. Alcohol and zolpidem both depress the central nervous system, and combining them significantly increases sedation, impairs coordination and judgment, and raises the risk of complex sleep behaviors and dangerous respiratory depression. Alcohol should be avoided entirely on any night zolpidem is taken.
Zolpidem is generally intended for short-term use, typically ranging from a few days to a few weeks, rather than indefinite nightly use. Extended use should be periodically reviewed with a physician, who can assess ongoing need, consider tapering, and discuss non-pharmacological approaches such as cognitive behavioral therapy for insomnia, which many sleep specialists regard as a preferred long-term strategy.
Zolpidem can impair driving-related skills the morning after a dose even when a patient feels fully awake, particularly at the 10 mg dose, with extended-release formulations, and in women due to slower clearance. Patients should not drive or perform tasks requiring full alertness until they understand how the medication affects them the following morning, and should exercise particular caution after any dose increase.
Reduced effectiveness over time, sometimes called tolerance, can occur with continued nightly use and should not be managed by independently increasing the dose. It should instead be discussed with a physician, who can assess whether a formulation change, a treatment break, the addition of behavioral sleep strategies, or a switch to a different approach altogether is the more appropriate next step.
Ambien (zolpidem) remains one of the most widely prescribed short-term treatments for insomnia, valued for its rapid onset and short elimination half-life when used correctly — taken immediately before a full night of sleep, on an empty stomach, and without alcohol or other sedating substances. Its immediate-release and extended-release formulations allow prescribers to match treatment to whether a patient's primary difficulty is falling asleep, staying asleep, or both.
The availability of generic zolpidem since 2007 has made this treatment accessible to a broad range of patients managing short-term insomnia, whether through a routine pharmacy prescription or a telehealth consultation. As with any Schedule IV controlled substance, zolpidem carries real risks — complex sleep behaviors, next-day impairment, dependence with extended use, and dangerous interactions with alcohol and other CNS depressants — that require full patient understanding and physician oversight from the first dose onward.
Within the parameters of a valid prescription, correct use, and appropriate medical supervision, Ambien and generic zolpidem have a well-established record as effective short-term tools for insomnia, best used as part of a broader approach to sleep health rather than as a standalone, indefinite solution.
Buy Ambien Online USA: Uses, Dosage & Safety Guide 2026
Buy Cialis Online USA: Uses, Dosage & Safety Guide 2026
Levitra (Verdanafil)
Buy Zopiclone Online USA: Complete Dosage, Safety & Usage Guide 2026